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Abstract: Until recently, patients with castration-resistant prostate cancer (CRPC) had limited 
therapeutic options once they became refractory to docetaxel chemotherapy, and no treatments 
improved survival. This changed in June 2010 when the Food and Drug Administration (FDA) 
approved cabazitaxel as a new option for patients with CRPC whose disease progresses during 
or after docetaxel treatment. For most of these patients, cabazitaxel will now replace mitoxan-
trone (a drug that was FDA-approved because of its palliative effects) as the treatment of choice 
for docetaxel-refractory disease. The approval of cabazitaxel was based primarily on the TROPIC 
trial, a large (n = 755) randomized Phase III study showing an overall median survival benefit 
of 2.4 months for men with docetaxel-pretreated metastatic CRPC receiving cabazitaxel (with 
prednisone) compared to mitoxantrone (with prednisone). Cabazitaxel is a novel tubulin-binding 
taxane that differs from docetaxel because of its poor affinity for P-glycoprotein (P-gp), an 
ATP-dependent drug efflux pump. Cancer cells that express P-gp become resistant to taxanes, 
and the effectiveness of docetaxel can be limited by its high substrate affinity for P-gp. Preclinical 
and early clinical studies show that cabazitaxel retains activity in docetaxel-resistant tumors, and 
this was confirmed by the TROPIC study. Common adverse events with cabazitaxel include 
neutropenia (including febrile neutropenia) and diarrhea, while neuropathy was rarely observed. 
Thus, the combination of cabazitaxel and prednisone is an important new treatment option for 
men with docetaxel-refractory metastatic CRPC, but this agent should be administered cau-
tiously and with appropriate monitoring (especially in men at high risk of neutropenic 
complications).
Keywords: cabazitaxel, castration-resistant prostate cancer, clinical trial, docetaxel resistance, 
drug development
Introduction
More than 217,000 men will be diagnosed with prostate cancer and 32,000 will die 
of metastatic prostate cancer in the United States (US) in 2010,1 making it the second 
leading cause of cancer death in American men, behind lung cancer. Most patients 
whose disease is diagnosed at the locoregional level have an excellent prognosis, 
enhanced by radical prostatectomy and/or radiation therapy. About one-fifth of patients 
undergo watchful waiting alone. A significant fraction (20%–40%) of patients who 
undergo primary therapy experience biochemical relapse (prostate-specific antigen 
[PSA] .0.2 ng/mL), and 30%–70% of those with biochemical recurrence develop 
metastatic disease within 10 years after local therapy.2–5 For most patients with metastatic 
prostate cancer, androgen-deprivation therapy, usually with a luteinizing hormone- 
releasing hormone (LHRH) agonist, improves symptoms but tumors invariably become Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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castration-resistant and patients develop progressive disease. 
Until the mid 1990s, with no known life-prolonging options, 
castration-resistant prostate cancer (CRPC) patients with 
progressive disease were generally treated with palliative 
approaches. Chemotherapy was not well tolerated by CRPC 
patients, who were often elderly men with limited bone mar-
row reserve and concurrent medical conditions.
In 1996, Tannock et al showed that mitoxantrone (with 
prednisone) improved quality of life and bone pain, and 
reduced serum PSA levels in men with CRPC,6 and this 
approach became the initial standard of care for such patients. 
Then in 2004, the TAX327 trial compared weekly and 
3-weekly docetaxel (and prednisone) against mitoxantrone 
(and prednisone) and showed a significant survival benefit for 
the 3-weekly docetaxel arm.7 That same year, the   Southwest 
Oncology Group reported significantly extended progression-
free and overall survival for CRPC patients treated with 
docetaxel and estramustine compared to mitoxantrone and 
prednisone.8 On the basis of these results, docetaxel replaced 
mitoxantrone as the first-line standard of care for CRPC 
patients. Until last year, however, physicians had no life-
prolonging second-line options after docetaxel failure. 
Notably, on June 17, 2010, the US Food and Drug Admin-
istration (FDA) approved cabazitaxel “for the treatment of 
patients with hormone-refractory metastatic prostate cancer 
previously treated with a docetaxel-containing regimen”.9 
This review summarizes the preclinical and clinical data that 
led to the FDA-approval of this agent, and touches upon the 
mechanism of action and rationale for the use of this drug in 
docetaxel-refractory disease. Our overall intention with this 
review is to raise awareness of a newly available second-line 
treatment for metastatic CRPC that provides an overall sur-
vival benefit.
Mechanism of action and biological 
rationale for cabazitaxel
Docetaxel is a widely-used second-generation taxane com-
pound. The first taxane was paclitaxel, a drug isolated from 
yew tree bark in the 1960s and first approved by the FDA in 
1992 for treatment of refractory ovarian cancer.10 Docetaxel 
is a semisynthetic and more active derivative of paclitaxel. 
Paclitaxel and docetaxel are both antimitotic cancer drugs 
that bind to intracellular microtubules, suppressing microtu-
bule dynamics. The taxanes promote or inhibit assembly of 
tubulin into microtubules, impairing the natural dynamics of 
microtubules and leading to mitotic block and apoptosis.10
In preclinical studies using advanced human tumors in 
mouse xenograft models, cabazitaxel was shown to be active 
in both docetaxel-sensitive tumors and those that did not 
respond to chemotherapy including docetaxel.11 The effec-
tiveness of paclitaxel and docetaxel is limited by the high 
substrate affinity of both agents for P-glycoprotein (P-gp), 
an adenosine triphosphate (ATP)-dependent drug efflux 
pump that decreases the intracellular concentrations of 
these drugs.12 It has been shown that cancer cells that express 
P-gp become resistant to taxanes.10,13 This resistance is con-
ferred by overexpression of the multidrug resistance (MDR1) 
gene that encodes P-gp, a member of the ATP-binding cas-
sette transporter family of proteins.14
Cabazitaxel (previously also known as XRP6258, 
TXD258, and RPR116258A) (Jevtana™; Sanofi-Aventis, 
Paris, France) is a semisynthetic taxane that uses a precursor 
molecule extracted from yew tree needles. It was selected 
for clinical development due to its poor affinity for P-gp 
and because it was superior to paclitaxel and docetaxel in 
penetration of the blood-brain barrier in preclinical models.15 
Cabazitaxel’s poor affinity for P-gp may or may not be the 
principal mechanism of action that enables its efficacy in 
the clinic. Multiple previous clinical trials have shown MDR1 
inhibitors to lack clinical efficacy.16
Chemistry and pharmacology
Chemical structure of cabazitaxel
Cabazitaxel was engineered as a dimethyloxy derivative of 
docetaxel (Figure 1) that offers two advantages over its 
predecessor. The primary benefit provided by the extra 
methyl groups is elimination of the P-gp affinity character-
istic of docetaxel, enabling cabazitaxel to be effective 
against docetaxel-refractory prostate cancer. The extra 
methyl groups also provide cabazitaxel with an uncommon 
capacity among chemotherapy agents; the ability to cross 
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Figure 1 Structure of cabazitaxel,11 a semi-synthetic taxane anticancer drug. (2a, 5b, 
7b, 10b, 13a)-4-acetoxy-13-({(2R,3S)-3 [(tertbutoxycarbonyl) amino]-2-hydroxy-3- 
phenylpropanoyl}oxy)-1-hydroxy-7,10-dimethoxy-9-oxo-5,20-epoxytax11-en-2-yl 
benzoat•propan-2-one(1:1);  C45H57NO14•C3H6O;  molecular  mass  =  894.01  units.   
The  red  circles  highlight  the  methoxy  side  chains  that  represent  the  primary 
substitution for the hydroxyl groups found in docetaxel.Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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the blood–brain barrier, the clinical effects of which remain 
to be investigated.17
Pharmacokinetics of cabazitaxel
Pharmacokinetic evaluations were performed using blood 
sampling from 170 patients. Following a 1-hour intravenous 
infusion of cabazitaxel (25 mg/m2), approximately 80% of 
the dose was eliminated within 2 weeks,15 primarily excreted 
by the enterohepatic circulation. The pharmacokinetic behav-
ior in plasma was best characterized by a triphasic model 
with a rapid initial-phase half-life averaging 4 minutes, 
  followed by an intermediate-phase half-life of 2 hours, and 
a prolonged terminal-phase half-life averaging 95 hours. 
  Protein binding of cabazitaxel was primarily to human serum 
albumin (82%) and lipoproteins;15 cabazitaxel is equally 
distributed between plasma and blood. Cabazitaxel is 
metabolized in the liver primarily by the CYP3A4/5 isoen-
zymes and to a lesser degree by CYP2C8. Although formal 
drug–drug interaction studies have not been completed, 
agents that induce or inhibit the activity of the CYP450 
isoenzymes should be avoided because of potential interac-
tion with cabazitaxel.18 The maximum plasma concentration 
(Cmax) of cabazitaxel in patients with solid tumors was 
535 µg/L and was reached at the conclusion of a one-hour 
infusion of 25 mg/m2 every 3 weeks.15 Average area-under-
the-curve (AUC) was 1,038 ± 299 µg-h/L, and the relation-
ship between cabazitaxel dose and AUC0–48h was proportional, 
as was the relationship between dose and Cmax.15
Clinical development
Phase i
In a Phase I study of cabazitaxel in 25 patients with advanced 
solid tumors, Mita et al administered intravenous doses of 
cabazitaxel at 10 mg/m2 (3 patients, 10 cycles), 15 mg/m2 
(6 patients, 25 cycles), 20 mg/m2 (9 patients, 48 cycles), and 
25 mg/m2 (7 patients, 19 cycles).15 The principal dose- 
limiting toxicity was neutropenia. One patient experienced 
prolonged grade 4 neutropenia, and a second patient 
  experienced febrile neutropenia, both at the 25 mg/m2 dose. 
Other toxicities included generally mild-to-moderate nausea, 
  vomiting, diarrhea, neurotoxicity, and fatigue. Diarrhea was 
observed in 14 patients (56%) during 28% of the courses of 
cabazitaxel; only one patient experienced grade 3 diarrhea.15 
No grade 3 or 4 neurotoxicities were observed, but grade 1 
neurosensory symptoms were common and manifested as 
acral paresthesia and diminished deep tendon reflexes 
as well as impaired vibratory sensation. No cumulative 
neurotoxicity was apparent in the nine patients receiving 
more than three courses at 20 or 25 mg/m2. Two patients 
experienced   flushing, dizziness, and chest tightness (grade 1 
hypersensitivity reactions); however in the setting of pre-
medication this did not reoccur. Two patients treated at 
25 mg/m2 experienced alopecia (grade 1/2).15
Anticancer activity was seen in two patients, both with 
metastatic prostate cancer.15 An 80-year-old man who 
received the 15 mg/m2 dose for six courses had a PSA decline 
from 62 to 21 ng/mL, experienced reduced disease-related 
bone pain, and demonstrated a reduction in a target lesion 
on computed tomography scan. He had previously undergone 
surgical castration, as well as treatment with bicalutamide, 
diethyl-stilbesterol, and mitoxantrone/prednisone. A 50-year-
old man with castration-resistant and docetaxel-refractory 
metastatic prostate cancer showed a confirmed partial 
response in measurable disease lesions and a PSA reduction 
from 415 to 44 ng/mL at the 25 mg/m2 dose level, but experi-
enced progressive disease after eight courses of chemotherapy. 
A partial response was also seen in one bladder cancer patient 
and minor responses were seen in two other patients, one of 
whom also had prostate cancer. Twelve patients (48%) had 
stable disease for greater than 4 months.15
Phase ii
No Phase II study of cabazitaxel in patients with advanced 
prostate cancer was ever conducted, but a Phase II evalu-
ation in breast cancer patients was central to the dosing 
selected for the eventual Phase III trial. Pivot et al conducted 
a Phase II study in 71 patients (61 evaluable) with metastatic 
breast cancer who were given intravenous cabazitaxel 
20 mg/m2 every 3 weeks. Patients received between 1 and 
25 cycles of cabazitaxel, with a median of four cycles. After 
the first cycle, 20 patients who had experienced no adverse 
events (.grade 3 toxicities) had their dose increased to 
25 mg/m2.19
After a median follow-up of 20 months, the median 
overall survival was 12.3 months and median time to progres-
sion was 2.7 months. Objective response rate was 14%, with 
eight partial and two complete responses seen. Eighteen 
patients (30%) experienced stable disease for at least 
3 months. Seventy-three percent of patients experienced 
neutropenia, 55% experienced leucopenia, 35% fatigue, 
32% nausea, 30% diarrhea, 18% vomiting, 17% sensory 
neuropathy, and 6% experienced hypersensitivity reactions. 
Two patients died within 30 days of their last on-study treatment. 
One death was due to shock with respiratory failure and 
determined to be related to the study drug. The cause of the 
other patient’s death was unknown.19Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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Phase iii
The safety and efficacy of cabazitaxel in men with metastatic 
prostate cancer was evaluated in a pivotal randomized, 
  multicenter, Phase III trial, TROPIC (treatment of hormone-
refractory metastatic prostate cancer previously treated with 
a docetaxel-containing regimen), that enrolled patients from 
January 2007 to October 2008.20 This study involved 146 
centers in 26 nations, and recruited 755 men with   metastatic 
CRPC who had progressed during (30% of patients) or after 
(70% of patients) receiving docetaxel-based   chemotherapy. 
Eligible patients were at least 18 years of age with an Eastern 
Cooperative Oncology Group (ECOG) performance status of 
0–2. Patients were required to have either rising PSA or mea-
surable disease as documented by Response Evaluation Criteria 
in Solid Tumors (RECIST),21 and had to be receiving LHRH 
agonist therapy or to have undergone surgical orchiectomy. 
Patients were allowed to continue bisphosphonates if the dose 
had remained stable for over 3 months. Median age of partici-
pants was 68 years (cabazitaxel) and 67 years (mitoxantrone), 
and 18.5% of patients were $75 years of age. Sixteen percent 
were non-Caucasian in both arms. Patients were stratified based 
on the presence/absence of measurable disease and on 
ECOG performance status, and then randomized equally into 
two groups: 378 patients received cabazitaxel (25 mg/m2), and 
377 received mitoxantrone (12 mg/m2). The chemotherapy 
agents were administered intravenously every 3 weeks for a 
maximum of 10 cycles. All patients concurrently received 
5 mg of oral prednisone twice daily.20
The trial’s primary endpoint was overall survival, and the 
main secondary endpoint was composite progression-free 
survival (defined as the time from randomization to the first 
date of PSA progression, radiographic tumor progression, pain 
progression, or death). Other secondary endpoints included 
PSA response rate ($50% reduction); PSA progression 
(increase by $25% over nadir); objective tumor response (for 
patients with measurable disease, based on RECIST); pain 
response (reduction of $two points from baseline pain level 
using the Present Pain Intensity scale); and time to radiographic 
progression. Impressively, median overall survival for the 
cabazitaxel arm was 15.1 months (95% confidence interval 
[CI]: 14.1–16.3 months) compared to 12.7 months (95% CI: 
11.6–13.7 months) in the mitoxantrone arm (P , 0.0001). 
Risk of all-cause mortality was reduced by 30% for men 
receiving cabazitaxel compared to those receiving mitoxan-
trone (hazard ratio 0.70, 95% CI: 0.59–0.83).20 Secondary 
analyses also showed significant improvements in time to 
tumor progression and time to PSA progression (summarized 
in Table 1). Overall pain reduction was similar between the 
two groups, with no significant differences found. However, 
since mitoxantrone is often used because of its favorable effects 
on pain reduction, these results suggest that cabazitaxel will 
offer patients similar palliative quality of life results.
The median number of treatment cycles delivered was six 
(95% CI: 3–10) for the cabazitaxel group and four (95% 
CI: 2–7) for the mitoxantrone group. Disease progression was 
the primary reason for treatment discontinuation in both 
groups. Treatment delays were reported in 28% of the 
cabazitaxel-treated patients and 15% of the mitoxantrone-
treated patients, and dose reductions were reported in 12% 
and 4% of patients, respectively. The most common toxicity 
in both treatment arms was neutropenia (82% of men in the 
cabazitaxel group and 58% in the mitoxantrone group expe-
rienced $grade 3 toxicity). Febrile neutropenia was observed 
in 8% and 1% of men, respectively. Given the high rates of 
neutropenia, prophylactic granulocyte-macrophage colony-
stimulating factor was allowed after the first chemotherapy 
cycle, according to physician discretion. Other adverse events 
are summarized in Table 2. The high rates of neutropenia and 
other adverse events may reflect a patient population with 
poor-prognosis disease (50% of men having measurable 
  disease, 25% having visceral metastases, and all having under-
gone previous chemotherapy treatment). Peripheral neuropathy 
Table 1 Primary and secondary endpoints in the TROPiC trial: response to treatment and disease progression
Cabazitaxel Mitoxantrone P-value
Primary endpoint
Overall survival (months) 15.1 (95% Ci: 14.1–16.3) 12.7 (95% Ci: 11.6–13.7) ,0.0001a
Secondary endpoints
PFS (months)b 2.8 (95% Ci: 2.4–3.0) 1.4 (95% Ci: 1.4–1.7) ,0.0001
Tumor response rate 14.4% (95% Ci: 9.6–19.3) 4.4% (95% Ci: 1.6–7.2) 0.0005
PSA response rate 39.2% (95% Ci: 33.9–44.5) 17.8% (95% Ci: 13.7–22.0) 0.0002
Pain response rate 9.2% (95% Ci: 4.9–13.5) 7.7% (95% Ci: 3.7–11.8) 0.63
Notes:  aCorresponds to a 30% relative reduction in risk of death (hazard ratio 0.70, 95% Ci: 0.59–0.83, P , 0.0001);  bProgression-free survival (PFS) is a composite 
endpoint defined as: the time between randomization and the first date of progression as measured by prostate-specific antigen (PSA) progression, tumor progression, pain 
progression, or death.Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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(all grades) was reported in 14% of patients in the cabazitaxel 
group and 3% of the patients in the   mitoxantrone group. 
However, only 1% of the patients in each group experienced 
grade 3 peripheral neuropathy.20
During the conduct of the TROPIC study, 74% of men 
on the mitoxantrone group and 61% on the cabazitaxel 
group died. In the mitoxantrone arm, three patients (1%) died 
due to adverse events: neutropenia/sepsis (one patient), 
dyspnea (one patient), and motor vehicle accident (one 
patient). In the cabazitaxel arm, 18 patients (5%) died from 
adverse effects: neutropenia/sepsis (seven patients), cardiac 
events (five patients), renal failure (three patients), dehydra-
tion (one patient), cerebral hemorrhage (one patient), and 
unknown cause (one patient).20
Table 3 collates and contrasts toxicity data from the 
TROPIC trial and the prior TAX327 study,7 which compared 
mitoxantrone/prednisone against docetaxel/prednisone as 
first-line therapy for metastatic CRPC. The table shows that 
the side effect profile of cabazitaxel may not be as favorable 
as that of mitoxantrone. The table also offers data on the 
toxicity of docetaxel. Given the caveats associated with 
cross-trial comparisons, direct comparison of cabazitaxel 
and docetaxel toxicity must await a future head-to-head 
study, but the data in Table 3 support a preliminary claim 
that cabazitaxel may be more problematic than docetaxel 
with respect to anemia and neutropenia.
Critical appraisal
The five cardiac-related deaths (one from ventricular fibril-
lation, one from sudden cardiac death, and three from cardiac 
arrest)22 combined with high incidence of neutropenia and 
febrile neutropenia bring into sharp focus the question of 
dose reduction strategies and personalization of cabazitaxel 
dosing for each patient. Multiple researchers recommended 
that the cabazitaxel dose level be lowered to 20 mg/m2.20,23,24 
Their concerns with the high dose are supported both by the 
20 mg/m2 recommended dose from the Phase I study of 
cabazitaxel15 as well as by the lower cardiac risk population 
of younger women with metastatic breast cancer recruited in 
the only Phase II study on the basis of which the Phase III 
dose was chosen.19 Based on our current data, the FDA label 
recommends the use of growth factor support as the primary 
prophylaxis in patients who are clinically considered at high 
risk for myelosuppression.11,25
An equally vexing question is whether and when to begin 
cabazitaxel treatment. Despite the FDA approval of cabazi-
taxel, some authors argue that further studies are needed 
before physicians routinely prescribe this expensive and toxic 
new drug. It has been pointed out that the inclusion criteria 
chosen by the TROPIC investigators biased the population 
toward healthier patients who received a lower cumulative 
dose of docetaxel thereby causing a meaningful enrichment 
of taxoid-responsive patients and favoring cabazitaxel over 
mitoxantrone.26
Finally, the approval of cabazitaxel by the FDA in June 2010 
was contingent upon several additional investigations that 
the manufacturer was required to conduct in the postmarket-
ing setting.9 These requirements are summarized below. 
Some of these studies are ongoing while others are currently 
in the planning phases.
To address the concerns of toxicities seen in patients 
receiving 25 mg/m2 of cabazitaxel, and to determine how 
cabazitaxel compares to docetaxel as a first-line treatment, a 
Table 2 Most frequent adverse events observed in the TROPiC 
study
Toxicity Cabazitaxel (n = 371) Mitoxantrone (n = 371)
Grade $ 3  
(%)
All grades  
(%)
Grade $ 3  
(%)
All grades   
(%)
Neutropenia 82% 94% 58% 88%
Diarrhea 6% 47% ,1% 11%
Fatigue 5% 37% 3% 27%
Back pain 4% 16% 3% 12%
Nausea 2% 34% ,1% 23%
vomiting 2% 23% 0% 10%
Hematuria 2% 17% 1% 4%
Abdominal pain 2% 12% 0% 4%
Peripheral  
neuropathy
1% 14% 1% 3%
Table 3 Selected grade 3/4 hematologic toxicities in the TAX327 and TROPiC trials
Toxicity Docetaxel Cabazitaxel  Mitoxantrone Mitoxantrone
TAX327 (n = 332) TROPIC (n = 371) TAX 327 (n = 335) TROPIC (n = 371)
Anemia  5% 10% 2% 5%
Neutropenia  32% 82% 22% 58%
Febrile neutropenia 2.7% 7.5% 1.8% 1.3%
Septic death  0% 0.3% 0.3% 0%Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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Phase III randomized controlled trial in patients with 
  castration-resistant metastatic prostate cancer is required that 
compares a) 75 mg/m2 of docetaxel, b) 25 mg/m2 of 
  cabazitaxel, and c) 20 mg/m2 of cabazitaxel. This study should 
be   powered to detect a 25% difference in overall survival, 
and should be designed to drop one of the cabazitaxel arms 
based on interim analysis of overall survival and safety.
To address the concerns of toxicities seen in patients 
receiving 25 mg/m2 of cabazitaxel, a Phase III randomized 
controlled trial in patients with castration-resistant metastatic 
prostate cancer previously treated with docetaxel is required, 
comparing a) 20 mg/m2 of cabazitaxel and b) 25 mg/m2 of 
cabazitaxel, powered to preserve 50% of the treatment effect 
of cabazitaxel 25 mg/m2.
A trial examining the effect of cabazitaxel on corrected 
QT (QTc) interval prolongation is required.
A trial to determine the pharmacokinetics and safety of 
cabazitaxel in patients with hepatic impairment is required. 
Two drug interaction trials are required to evaluate the effect 
of strong CYP3A4 inhibitors (eg, ketoconazole) and strong 
CYP3A inducers (eg, rifampin) on the pharmacokinetics of 
cabazitaxel.
Current treatment options,  
new agents, and future directions
Cabazitaxel is one of a series of drugs currently being evalu-
ated by the FDA and is not the only treatment to be approved 
for CRPC in 2010. Sipuleucel-T (Provenge, Dendreon 
  Corporation, Seattle, WA), the first therapeutic immuno-
therapy available for any cancer, was approved by the FDA 
on April 29, 2010 for men with asymptomatic or minimally 
symptomatic metastatic CRPC, on the basis of improved 
median survival observed in a pivotal placebo-controlled 
Phase III trial (overall survival 25.8 months versus 21.7 months 
for placebo) and an increase in 3-year survival (31.7% 
versus 23.0%).27 Thus, sipuleucel-T provides a second option 
beyond docetaxel for the treatment of men with metastatic 
CRPC. Of note, although the majority of patients in that study 
were chemotherapy-naïve, a number of men (about 15%) 
had received prior treatment with docetaxel.27 In addition, in 
  October 2010, overall survival results were presented from a 
Phase III placebo-controlled clinical trial of abiraterone ace-
tate, a CYP17 inhibitor that impairs extra-gonadal androgen 
synthesis, demonstrating an overall survival advantage in men 
with metastatic docetaxel-pretreated CRPC randomized to 
abiraterone or placebo (median survival 14.8 versus 
10.9 months).33 These are examples of an encouragingly large 
variety of new agents that have made their way into Phase III 
clinical trials in metastatic CRPC, and have added to the 
therapeutic arsenal in this disease. Table 4   summarizes efficacy 
and toxicity data for some of the new agents described above, 
and also   highlights several other promising drugs which are 
also currently in Phase III development.
At present, cabazitaxel is confined to post-docetaxel 
second-line therapy, but an upcoming head-to-head compari-
son against docetaxel could change that situation.23 In   addition, 
two trials of cabazitaxel in combination with other agents 
have been launched. These trials combine cabazitaxel with 
cisplatin (NCT00925743) and cabazitaxel with gemcitabine 
(NCT01001221), both in the Phase I/II setting in advanced 
solid tumors. Even more promising in the post-docetaxel 
space may be trials that will combine cabazitaxel with the 
next generation of androgen-inhibiting agents such as abi-
raterone and MDV3100. If cabazitaxel also acts through 
androgen receptor signaling (as does docetaxel), there could 
be synergistic effects from such combinations.23 Finally, 
other investigators are planning a Phase I trial combining 
cabazitaxel with mitoxantrone and prednisone in patients 
with metastatic CRPC who have not previously been treated 
with chemotherapy for metastatic disease. This strategy relies 
on the fact that these two chemotherapeutic agents have 
nonoverlapping patterns of toxicity.
Financial considerations  
for cabazitaxel
The market for docetaxel was $2.6 billion in 2009, accounting 
for more than half of the $4.6 billion market for plant-derived 
anticancer agents. Between 2004 and 2009, the market for 
all plant-derived anticancer drugs grew at 3% per year.28 
Because many CRPC patients become refractory to docetaxel 
chemotherapy or develop grade 3/4 toxicities within 
4–6 months of docetaxel treatment, the eventual market for 
cabazitaxel may be expected to be comparable to that of 
docetaxel. Furthermore, the price per cycle for cabazitaxel 
is US$5, 598,29 which is more than twice the cost per cycle 
of docetaxel (US$2, 483),30 underpinning financial analysts’ 
estimates that cabazitaxel sales may grow to US$300 million 
by 2013 and US$500 million by 2016.31 Because these esti-
mates only reflect the second-line use of cabazitaxel, the 
market for this agent could rise even further if it is also 
approved for first-line use in men with CRPC.
Conclusion
Treatment with cabazitaxel and prednisone was approved by 
the FDA in June 2010 as the first therapy that offers a survival 
benefit in men with metastatic CRPC whose disease   progresses Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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during or after docetaxel treatment. The TROPIC trial showed 
a significant overall survival advantage of 2.4 months using 
second-line cabazitaxel over mitoxantrone in such patients. 
Because of the large incidence of febrile neutropenia (and 
neutropenic deaths), this agent should be administered cau-
tiously and with appropriate monitoring. To this end, careful 
patient selection, and use of concurrent growth factor support, 
is paramount for the safe prescribing of this novel taxane 
agent. Dose-reductions to 20 mg/m2 may often be necessary, 
and this lower dose will now be   incorporated into future trials. 
The modest survival benefit observed with cabazitaxel may 
be even greater if combined judiciously with other targeted 
therapies, ultimately resulting in a cumulative improvement 
in the lifespan of metastatic CRPC patients. Finally, the 
comparative effectiveness of cabazitaxel versus docetaxel in 
the first-line setting remains to be defined.
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